Results 141 to 150 of about 19,867 (255)
Oncolytics, Cancer-Fighting Viruses from Past to Future: A Literature Review [PDF]
پیاورد سلامتBackground and Aim: Oncolytic viruses, as novel and advanced tools in the field of treating various types of cancer, have played a very important role in medical developments.
Seyedeh Nasim Mirbahari +4 more
doaj
The Potency of Mesenchymal Stem Cells as Viral Oncolytic Carriers
Clinical and Research Journal in Internal MedicineOncolytic viruses (OVs) represent a category of viruses that selectively replicate within tumor cells, destroying cancer cells through a dual mechanism involving viral oncolysis and the stimulation of the host's anti-tumor immune response.
Muhammad Farid Rakhman
doaj +1 more source
Advances in Cancer Immunotherapy for Solid Tumors
Advanced Science, Volume 13, Issue 35, 24 June 2026.Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz +1 more
wiley +1 more source
, 2008 With the aim of improving viral distribution and tumor penetration, we have engineered decorin expressing replication-incompetent (dl-LacZ-DCNG) and -competent (Ad-[DELTA]E1B-DCNG) adenoviruses.
Joo-Hang Kim +7 more
core
Targeting tumor vasculature through oncolytic virotherapy: recent advances
, 2015 The oncolytic virotherapy field has made significant advances in the last decade, with a rapidly increasing number of early- and late-stage clinical trials, some of them showing safety and promising therapeutic efficacy.
Merchan, Jaime R +1 more
core +1 more source
Integrating Oncolytic Virus Engineering and Delivery Strategies for Enhanced Cancer Virotherapy
Aggregate, Volume 7, Issue 6, June 2026.Integrated engineering strategies combining oncolytic virus (OV) design with advanced delivery platforms overcome biological barriers and enhance cancer virotherapy. Genetic engineering improves viral potency and selectivity, while local and systemic delivery systems promote viral protection, tumor targeting, penetration, and tumor microenvironment ...
Jiliang Zhao +5 more
wiley +1 more source
Immunogenic Cell Death: Unlocking New Frontiers in Cancer Immunotherapy
Cancer Innovation, Volume 5, Issue 3, June 2026.Immunogenic cell death ICD is a specific type of stress‐induced cell death that results in adaptive immune response and generating an immunological memory. The development of strategies that induce ICD are considered highly effective in the treatment of cancer within the bounds of immunotherapy.
Katherine Yaacoub
wiley +1 more source
Cancer Medicine, Volume 15, Issue 6, June 2026.ABSTRACT Background Concomitant medications (CMs) influence outcomes in patients receiving immune checkpoint inhibitors (ICIs), but their impact in sarcoma remains undefined. We assessed the association between CM use and ICI outcomes in patients with advanced or metastatic sarcoma. Methods This pooled analysis included patients from seven investigator‐
Adel Shahnam +16 more
wiley +1 more source
Oncolytic Viruses for Multiple Myeloma Therapy
, 2018 Although recent treatment advances have improved outcomes for patients with multiple myeloma (MM), the disease frequently becomes refractory to current therapies.
Christine Calton +8 more
core +1 more source
Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control
Cancer Reports, Volume 9, Issue 6, June 2026.ABSTRACT Background Hematologic disorders, including sickle cell disease, anemias, hemoglobinopathies, leukemias, lymphomas, and bleeding disorders, constitute a substantial and growing burden of morbidity and mortality across Africa. Structural health system constraints—limited diagnostic capacity, shortages of trained hematology specialists ...
Emmanuel Ifeanyi Obeagu
wiley +1 more source